Buy Lorista coated tablets 100mg N60

Lorista coated pills 100mg N60

Condition: New product

1000 Items


More info

Active ingredients


Release form



Potassium losartan 100 mg adjuvants: cellactose (a mixture of lactose monohydrate and cellulose), pregelatinized starch, maize starch, microcrystalline cellulose, anhydrous colloidal silicon dioxide, magnesium stearate composition of the shell: hypromellose, propylene glycol, hypomellose, talc, glycol, anhydrous, magenta starch;


- arterial hypertension; - reducing the risk of stroke in patients with arterial hypertension and left ventricular hypertrophy; - chronic heart failure (as part of combination therapy, with intolerance or ineffectiveness of ACE inhibitor therapy); - protection of kidney function in patients with type 2 diabetes proteinuria to reduce proteinuria, reduce the progression of kidney damage, reduce the risk of end-stage development (to prevent the need for dialysis, the likelihood of icheniya serum creatinine) or death.


- arterial hypotension; - hyperkalemia; - dehydration; - lactose intolerance; - galactosemia or impaired glucose / galactose absorption syndrome; - pregnancy; - lactation period; - age up to 18 years (efficacy and safety not established); - increased sensitivity to Losartan and / or other components of the drug. The drug should be used with caution in case of hepatic and / or renal failure, reduced BCC, impaired water and electrolyte balance, bilateral renal artery stenosis or arterial stenosis th kidney.

Precautionary measures

During treatment, psoriasis may worsen. During pheochromocytoma, propranolol can only be used after taking an alpha blocker. After a long course of treatment, propranolol should be discontinued gradually, under the supervision of a physician. during anesthesia, you must stop taking propranolol or find a remedy for anesthesia with minimal negative inotropic effects. Influence on ability to drive motor transport and control mechanisms of patients whose activities require increased attention,the question of the use of propranolol on an outpatient basis should be resolved only after evaluating the individual response of the patient.

Dosage and administration

The drug is taken orally, regardless of the meal, the frequency of administration is 1 time per day. In hypertension, the average daily dose is 50 mg. The maximum antihypertensive effect is achieved within 3-6 weeks of therapy. It is possible to achieve a more pronounced effect by increasing the dose of the drug up to 100 mg / day in two doses or in one dose. Against the background of diuretic intake in high doses, it is recommended to start Loristoy therapy with 25 mg / day in one dose. For elderly patients and patients with impaired function kidney (including patients on hemodialysis) does not require correction of the initial dose of the drug. Patients with impaired liver function should be given a lower dose. In chronic heart failure, the initial dose of the drug is 12.5 mg / day in one step. In order to achieve the usual maintenance dose of 50 mg / day, the dose must be increased gradually, at intervals of 1 week (for example, 12.5 mg, 25 mg, 50 mg / day). Lorista is usually prescribed in combination with diuretics and cardiac glycosides. To reduce the risk of stroke in patients with arterial hypertension and left ventricular hypertrophy, the standard initial dose is 50 mg / day. In the future, low doses of hydrochlorothiazide may be added and / or the dose of Loristy may be increased to 100 mg / day. To protect the kidneys in patients with type 2 diabetes with proteinuria, the standard initial dose of Loristy is 50 mg / day. The dose of the drug can be increased to 100 mg / day, taking into account the reduction of blood pressure.

Side effects

From the side of the central nervous system and peripheral nervous system: ≥1% - dizziness, asthenia, headache, fatigue, insomnia; <1% - anxiety, sleep disturbance, drowsiness, memory disorders, peripheral neuropathy, paresthesia, hypostezia, migraine, tremor, ataxia, depression, syncope. On the part of the cardiovascular system: orthostatic hypotension (dose-dependent), palpitations, tachycardia, bradycardia, arrhythmias, angina pectoris, vasculitis. Respiratory system: ≥1% - nasal congestion, cough *, infections of the upper respiratory tract, pharyngitis, dyspnea, bronchitis, swelling of the nasal mucosa. From the alimentary system: ≥1% - nausea, diarrhea *,dyspeptic symptoms *, abdominal pain; <1% - anorexia, dry mouth, toothache, vomiting, flatulence, gastritis, constipation, hepatitis, abnormal liver function; very rarely - increased activity of liver enzymes, hyperbilirubinemia. From the urinary system: <1% - urgency to urinate, urinary tract infections, renal dysfunction; sometimes - a moderate increase in the level of urea and creatinine in the serum. From the reproductive system: <1% - decreased libido, impotence. From the musculoskeletal system: ≥1% - convulsions, myalgia *, back pain, chest pain ; <1% - arthralgia, arthritis, pain in the shoulder, knee, fibromyalgia. From the sensory organs: <1% - tinnitus, taste disturbance, visual disturbances, conjunctivitis. From the hematopoietic system: infrequently - anemia, Schoenlein-Genoh purpura Dermatological reactions: <1% - dry skin, erythema, photosensitization, increased sweating, alopecia. On the part of the metabolism: hyperkalemia, gout. Allergic reactions: <1% - urticaria, skin rash, pruritus, angioedema (including laryngeal edema and tongue causing airway obstruction and / or swelling face, lips, pharynx). Sometimes angioedema developed earlier when taking other medicines, including ACE inhibitors. * - side effects, the incidence of which is comparable to placebo. In most cases, Lorista is well tolerated, side effects are mild and transient in nature and do not require discontinuation of the drug.